ReviewPHAGE (New Rochelle, N.Y.)2024
A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections.
Review in PHAGE (New Rochelle, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Phage and CRISPR based precision antimicrobials: a dual strategy against multidrug-resistant bacteria.Molecular biology reports · 2026Review
- Molecular and environmental drivers of antimicrobial resistance: global epidemiology, resistome dynamics, and one health strategies.Archives of microbiology · 2026Review
- Evolutionary interplay: virulence, endolysin-like hydrolases, and defense correlations in the Erwinia amylovora pangenome.BMC microbiology · 2026Article
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Genomic landscape of biosynthetic gene clusters in Iranian extremophiles reveals prolific metabolite potential, prophage associations, and integrated defensive-metabolic islands.BMC microbiology · 2026Article
- Colistin Resistance in Gram-Negative Bacteria: Mechanisms, Transmission, and Novel Intervention Strategies.Microorganisms · 2026Review
- Bacteriophage therapy against multidrug resistant bacterial infections demonstrates clinical advances and engineering innovations between 2020-2026.Frontiers in microbiology · 2026Review
- Wounds and the Microbiota: The Healing Interplay Between Host and Microbial Communities.International journal of molecular sciences · 2025Review
- Bridging the gap: Phage manufacturing processes from laboratory to agri-food industry.Virus research · 2025Review
- From Abnormal Uterine Bleeding to Malignancy: The Role of Hormonal Profiling and Histopathology in Early Detection of Endometrial Carcinoma.Advanced biomedical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rising antibiotic resistance among bacterial pathogens has become a substantial health issue for human civilization. The emergence of these pathogens in high-risk diseases such as cystic fibrosis (CF) has led to financial and nonfinancial losses, necessitating alternative therapies. This study presents an overview of such approaches, including phage therapy, antimicrobial peptides (AMPs), nanotechnology, monoclonal antibodies (mAbs), microbial therapies (probiotic therapy), clustered regularly interspaced short palindromic repeats technology (CRISPR), and aptamers focusing on their mechanisms of action and exploring the impact of combining phage and phage derivatives with the mentioned approaches. Although alternative approaches and their combinations with phages show promise, the phage-antibiotic combination has been the subject of most studies, and It has been proven to be highly effective in combating antibiotic-resistant infections. Other combinations also appear promising, but further studies are needed to determine their effectiveness. This emphasizes the need for more thorough research into different phage combination treatments beyond the well-established phage-antibiotic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.